FDA approves Pharmacyclics' ibrutinib for MCL

|By:, SA News Editor

The FDA has approved Pharmacyclics' (PCYC) ibrutinib for mantle cell lymphoma.

The drug is co-marketed with Janssen (JNJ).

This marks the second drug with Breakthrough Therapy Designation to win approval.

The drug is "intended for patients who have received at least one prior therapy."

Also approved for MCL: Celgene's (CELG) Revlimid.

Full FDA release